Health
NCCN Awards Funding to Improve Care for People with Breast Cancer
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced new funding for quality improvement initiatives in breast cancer to help advance patient outcomes. This initiative is made possible through funds provided by Novartis Pharmaceuticals Corporation.
About this update from Novartis Ag
[{"type":"text","content":"The National Comprehensive Cancer Network Oncology Research Program announces funding for researchers from Indiana University Melvin and Bren Simon Comprehensive Cancer Center, UC Davis Comprehensive Cancer Center, University of Washington School of Medicine, and Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine in collaboration with Novartis, an innovative medicines company.","length":395,"tagName":"p"},{"type":"text","content":"PLYMOUTH MEETING, Pa., Oct. 1, 2025 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced new funding for quality improvement initiatives in breast cancer to help advance patient outcomes. This initiative is made possible through funds provided by Novartis Pharmaceuticals Corporation.","length":346,"tagName":"p"},{"type":"image","alt":"Left to right: Drs. Ademuyiwa, Dang, Kimble-Hill, and Marcotte. Learn more at NCCN.org/ORP.","displaySize":"","headline":null,"caption":"Left to right: Drs. Ademuyiwa, Dang, Kimble-Hill, and Marcotte. Learn more at NCCN.org/ORP.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":125,"url":"https://media.zenfs.com/en/prnewswire.com/920d7d91c82527b0a2ddc707c3c01a2b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Obkh0B.kEOjI.dwLsuQyPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/920d7d91c82527b0a2ddc707c3c01a2b","width":400,"height":125}},"href":"https://mma.prnewswire.com/media/2785951/National_Comprehensive_Cancer_Network_Headshots.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Breast cancer is the most commonly diagnosed cancer and the second leading cause of death in women in the United States. More than 300,000 new cases of breast cancer are estimated to be diagnosed in 2025. The 5-year relative survival rate varies greatly based on stage at diagnosis, with a higher than 90% survival rate for stage I but less than 30% for stage IV1. The aim of these studies is to optimize outcomes across the spectrum of breast cancer care, including, but not limited to, screening, diagnosis, treatment, and survivorship.","length":538,"tagName":"p"},{"type":"text","content":""People with breast cancer are living longer, in part due to novel therapeutics. We have an opportunity to improve and exte...